Not only was Oregon the first state to decriminalize pot in 1973, years before its glamorous neighbor to the south, but its medical marijuana program has operated with few glitches since it began in 1998. Now, it's an issue in a top statewide election race.
Based on my discussions with several analysts, from reading their reports, I suspect that the earnings revisions occurred after the analysts had conversations with Mylan.
Discussing why he thinks the affordable care act is not a coherent bill, with Lawrence Lindsey, former National Economic Council director, The Lindsey Group president/CEO.
If you’re a professional athlete, injuries are almost guaranteed. However, sometimes the off-field injuries are so bizarre they become noteworthy.
Sickness and disease are part of the human condition. There will be stunning advances in health care in the coming decades — and many new challenges.
Despite the perception about a lack of work, there are jobs that employers can’t fill. Applicants may lack training, or the jobs may not pay enough. Whatever the reason, jobs in many major sectors going unfilled.
India’s mass production of generic versions of drugs patented elsewhere helps poor people with treatment that would otherwise be too costly, but drug companies say the knockoffs stifle innovation. The New York Times reports.
Merck said Tuesday first-quarter earnings would fall below Wall Street's estimates, however, it still expects to reach its earnings forecast for the full year.
There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."
Insight on the biotech firm seeing shares down after announcing some patients treated with its hepatitis C drug experienced a relapse, with Mark Schoenebaum, ISI Group
A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.
It’s rare for the world's leading pharmaceutical companies and other partners to work together to tackle an urgent global health issue. It’s time for this to change and our new coordinated effort – unlike previous siloed, disease-by-disease approaches – is the first step.
Paula Deen has been teaching comfort food cooks since 2002. On January 17, 2012, she announced her diagnosis of Type 2 diabetes. She also announced that she had become the spokesperson for the anti-diabetes drug Victoza. However, she’s hardly the only celebrity chef to make a questionable endorsement deal.
CNBC's Steve Liesman has details on a new study showing the hidden costs of home foreclosure showing up in a completely different part of the economy: health care.
International Living just released its Retirement Index for 2012, which determines foreign destinations offering retirees a high standard of living at a low price. CNBC.com highlights 10 of them.
Dendreon's revenues for its solo product, Provenge, has more than tripled from a year ago. Insight on the drug's treatment of prostate cancer and an outlook on the healthcare sector, with Mitchell Gold, Dendreon president/CEO.
The nicotine gum and patches that millions of smokers use to help kick their habit have no lasting benefit and may backfire in some cases, according to the most rigorous long-term study to date of so-called nicotine replacement therapy. The New York Times reports.
A check up on the health care sector, with Chris Viehbacher, Sanofi-Aventis CEO, who shares his outlook for 2012.
We are seeing a slow recovery in the U.S. and while there are challenges there are opportunities to take advantage of the slow recovery, says William Weldon, Johnson & Johnson chairman/CEO.